Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment Approaches for Altered Facial Expression: A Systematic Review in Facioscapulohumeral Muscular Dystrophy and Other Neurological Diseases.
Rasing NB, van de Geest-Buit WA, Chan OYA, Mul K, Lanser A, van Engelen BGM, Erasmus CE, Fischer AH, Ingels KJAO, Post B, Siemann I, Groothuis JT, Voermans NC. Rasing NB, et al. Among authors: van engelen bgm, van de geest buit wa. J Neuromuscul Dis. 2024;11(3):535-565. doi: 10.3233/JND-230213. J Neuromuscul Dis. 2024. PMID: 38517799 Free PMC article.
Living with facioscapulohumeral muscular dystrophy during the first two COVID-19 outbreaks: a repeated patient survey in the Netherlands.
Deenen JCW, Kools J, Greco A, Thewissen R, van de Put W, Lanser A, Joosten LAB, Verbeek ALM, van Engelen BGM, Voermans NC. Deenen JCW, et al. Among authors: van engelen bgm, van de put w. Acta Neurol Belg. 2024 Apr;124(2):559-566. doi: 10.1007/s13760-023-02443-3. Epub 2024 Jan 13. Acta Neurol Belg. 2024. PMID: 38218752 Free PMC article.
An up-to-date myopathologic characterisation of facioscapulohumeral muscular dystrophy type 1 muscle biopsies shows sarcolemmal complement membrane attack complex deposits and increased skeletal muscle regeneration.
Hubregtse L, Bouman K, Lama C, Lassche S, de Graaf N, Taglietti V, Küsters B, Periou B, Relaix F, van Engelen B, Authier FJ, Voermans NC, Malfatti E. Hubregtse L, et al. Neuromuscul Disord. 2024 Mar;36:6-15. doi: 10.1016/j.nmd.2024.01.003. Epub 2024 Jan 14. Neuromuscul Disord. 2024. PMID: 38306719 Free article.
The capability approach in rehabilitation: developing capability care.
Pijpers EJ, Bloemen B, Cup EHC, Groothuis JT, Oortwijn WJ, van Engelen BGM, van der Wilt GJ. Pijpers EJ, et al. Among authors: van engelen bgm, van der wilt gj. Disabil Rehabil. 2025 Feb;47(3):762-774. doi: 10.1080/09638288.2024.2342494. Epub 2024 Apr 16. Disabil Rehabil. 2025. PMID: 38625146 Free article.
Nerve enlargement in patients with Noonan syndrome: A retrospective cohort study.
Draaisma F, Leenders EKSM, Erasmus CE, Braakman HMH, Burgers MCJ, Coppens CH, Rinne T, Zenker M, Tartaglia M, Reintjes W, Voermans NC, van Engelen BGM, van Alfen N, Draaisma JMT. Draaisma F, et al. Among authors: van alfen n, van engelen bgm. Am J Med Genet A. 2024 Nov;194(11):e63810. doi: 10.1002/ajmg.a.63810. Epub 2024 Jul 3. Am J Med Genet A. 2024. PMID: 38958480
An open-label pilot study of losmapimod to evaluate the safety, tolerability, and changes in biomarker and clinical outcome assessments in participants with facioscapulohumeral muscular dystrophy type 1.
Kools J, Voermans N, Jiang JG, Mitelman O, Mellion ML, Ramana V, van Engelen BGM. Kools J, et al. Among authors: van engelen bgm. J Neurol Sci. 2024 Jul 15;462:123096. doi: 10.1016/j.jns.2024.123096. Epub 2024 Jun 15. J Neurol Sci. 2024. PMID: 38959779 Free article. Clinical Trial.
335 results